Feb 16 (Reuters) - Sequenom Inc SQNM.O launched its fetal test for sex determination based on its SEQureDx technology, which had been hit by a scandal over employee mishandling of research and data.
Shares of the company were up 4 percent at $4.69 in premarket trade on Tuesday. They closed at $4.52 Friday on Nasdaq.
SensiGene Fetal is the second test launched this month based on the technology. Earlier, it had launched a test to detect any incompatibility between the mother’s and the fetus’ blood type.
In April last year, the company delayed the launch of a Down syndrome test and said it was no longer relying on previously announced research and development test data and results related to its SEQureDx technology. (Reporting by Jennifer Robin Raj in Bangalore; Editing by Aradhana Aravindan)